Skip to main content
Fig. 4 | World Journal of Surgical Oncology

Fig. 4

From: RBM14 as a novel epigenetic-activated tumor oncogene is implicated in the reprogramming of glycolysis in lung cancer

Fig. 4

YY1 alters H3 acetylation in RBM14 promoter by recruiting to EP300. A, B ChIP assay was used to evaluate the accumulation of EP300 in RBM14 promoter. ***p<0.001 vs IgG. C The co-IP assay was used to affirm the interaction between EP300 and YY1 in PC9 and A549 cells. D, E ChIP assay was used to evaluate the accumulation of YY1, EP300, H3K9ac, and H3K27ac in RBM14 promoter after YY1 overexpression. ***p<0.001 vs Vector. F, G The mRNA level of YY1, EP300, and RBM14 in A549 and H1299 cells was detected after YY1 overexpression. ***p<0.001 vs vector. Three independent experiments were performed

Back to article page